The Role of New Technologies in Enabling Cell and Gene Therapies, BIO Digital

 
BIO2020-ParticipantSocial-Speaker-wide (1).png

Previously Recorded BIO Digital 2020 Panel, Sponsored by BioProcess Theatre, Chaired by:  Doug Miller, Managing Director, BPTG, BDO

Panelists:
Daniella Kranjac, Founding Partner, Dynamk Capital LLC
Tim Kelly, President of Manufacturing, Asklepios BioPharmaceutical, Inc
Andy Ramelmeier, Executive Vice President of Technical Operations, Sangamo Therapeutics, Inc.
Ran Zheng, Chief Technical Officer, Orchard Therapeutics

Register and view the virtual panel.

A panel of experts will discuss product development and manufacturing challenges for cell and gene therapies, and technologies that are being developed to address these challenges.  Panelists will include both end users that can discuss the needs for new technologies as well as technology providers.

The panel will discuss technologies for:

  • Scalable and cost efficient production of viral vectors for gene therapy

  • Non-viral approaches for gene therapy

  • Scaling up to meet demand for autologous cell therapies

Daniella Kranjac